Menu
Back to Journals » Journal of Multidisciplinary Healthcare » Volume 17
CA125-Associated Activated Partial Thromboplastin Time and Thrombin Time Decrease in Patients with Adenomyosis [Letter]
Received 22 January 2024
Accepted for publication 25 January 2024
Published 26 January 2024 Volume 2024:17 Pages 405—406
DOI https://doi.org/10.2147/JMDH.S460854
Checked for plagiarism Yes
Editor who approved publication: Dr Scott Fraser
Zainarda,1,2,* Hasta Handayani Idrus3,*
1Faculty of Medicine, Hasanuddin University, Makassar, Indoensia; 2Department of Orthopedic, Dody Sarjoto Hospital, Makassar, Indoensia; 3Biomedical Research Center, Research Organization for Health, National Research and Innovation Agency, Cibinong Science Center, Cibinong - Bogor, West Java, Indonesia
*These authors contributed equally to this work
Correspondence: Zainarda, Department of Orthopedic, Dody Sarjoto Hospital, Makassar, Indoensia, Email [email protected]
View the original paper by Dr Yang and colleagues
Dear editor
We have read the paper by Yang et al on CA125-Associated Activated Partial Thromboplastin Time and Thrombin Time Decrease in Patients with Adenomyosis.1 We congratulate the authors for providing new information regarding the CA125 antigen in relation to hypercoagulability and thrombosis in adenomyosis patients. This is quite important because coagulation parameters must be detected on time and closely monitored to prevent thrombosis, besides that the CA125 antigen also has a pattern of changes in levels which is different for each patient after surgery, this can help medical personnel in determining the patient’s prognosis after surgery.2
The study conducted by Yang et al aimed to explore more deeply the changes and factors that influence the coagulation parameter, namely CA125, in patients with adenomyosis and obtained the results that CA125 levels in the adenomyosis group were significantly higher than in the leiomyoma group.1 However, thrombin time was shorter in the adenomyosis group compared with the leiomyoma and control groups. The results obtained are in line with the objectives the author wants to achieve. However, it is necessary to consider using more than one antigen to increase the specificity and sensitivity of the examination carried out, for example we recommend the combination of MPV and CA125, RDW and CA125, because it can significantly help in increasing the accuracy of diagnosis by doctors.3 Other studies also reveal that the combination of CA125 and GLS or CA125, FASN and GLS can increase sensitivity, specificity and accuracy in predicting suboptimal cytoreductive surgery. It is hoped that this combination can help doctors provide better therapy.4
In conclusion, we agree that the shortening of APTT and TT related to CA125 shows the importance of early detection of coagulation parameters in patients with elevated CA125 levels to determine hypercoagulability and prevent thrombi in adenomyosis.1 However, several studies have found that CA-125 is not a strong enough predictor if stands alone in diagnostic screening, but it requires a combination of several biomarkers which also play a role in predicting and preventing thrombosis, therefore it is necessary to carry out further research with larger samples so that the results of this research will continue to develop.2
Disclosure
The authors report no conflicts of interest in this communication.
References
1. Yang F, Wang Q, Deng F, Liu J. CA125-associated activated partial thromboplastin time and thrombin time decrease in patients with adenomyosis. J Multidiscip Healthc. 2024;17(January):251–261. doi:10.2147/JMDH.S435365
2. Luo X, Lin X, Lin R, et al. The CA125 level postoperative change rule and its prognostic significance in patients with resectable pancreatic cancer. BMC Cancer. 2023;23(1):1–9. doi:10.1186/s12885-023-11346-8
3. Qin YY, Wu YY, Xian XY, et al. Single and combined use of red cell distribution width, mean platelet volume, and cancer antigen 125 for differential diagnosis of ovarian cancer and benign ovarian tumors. J Ovarian Res. 2018;11(1):4–9. doi:10.1186/s13048-018-0382-3
4. Winarno GNA, Hidayat YM, Soetopo S, Krisnadi SR, Tobing MDL, Rauf S. The role of CA-125, GLS and FASN in predicting cytoreduction for epithelial ovarian cancers. BMC Res Notes. 2020;13(1):1–7. doi:10.1186/s13104-020-05188-x
© 2024 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.